Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study
- PMID: 1487411
- DOI: 10.1007/BF00944194
Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study
Abstract
Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical